CANC: TEMA ONCOLOGY ETF
What this ETF is trying to do
The TEMA Oncology ETF (CANC) focuses on the oncology sector, which involves companies working on cancer treatments. It holds a variety of companies, including large pharmaceutical firms and smaller biotech businesses.
Top Holdings
As of October 7, 2026, the fund holds 60 different assets. Because the list is partial, we only see the largest holdings. The top five include:
• Revolution Medicines Inc: 6.05%
• Eli Lilly and Co: 4.93%
• Cogent Biosciences Inc: 4.92%
• Novartis AG: 4.01%
• Roche Holding AG: 3.76%
What the numbers show
The current price of the ETF is $41.35. To understand how the price has changed, we can look at the price return (which tracks only the share price) and the total return (which includes distributions).
• Year-to-Date (YTD): The price return and total return are both approximately 19.10%.
• One Year: The price return was 39.82%, while the total return was 39.90%.
• Three Year: The price return was 78.89%, and the total return was 85.05%.
• Five Year: The total return was -37.32%.
For a simple example, if you had invested $10,000 based on the estimated price from roughly one year ago ($29.57), the price-only growth would have turned that into approximately $13,981.61.
Income and distribution explanation
This ETF has a distribution yield of 0.05%. It pays out distributions irregularly and has only made one payout in the last 12 months.
It is important for new investors to remember that a distribution yield is not the same as a total return. While distributions provide cash income, they do not guarantee that the original investment value will stay the same.
NAV erosion explanation
"NAV erosion" happens when the underlying value of an ETF's assets drops over time. This ETF has an erosion-risk score of 100, and the label states "No price erosion detected." The erosion severity is listed as "good," and there is no severe erosion-risk flag.
Pros
• The ETF has shown strong positive price and total returns over the last one and three years.
• There is currently no detected NAV erosion.
Cons
• The five-year total return is negative (-37.32%).
• Distributions are infrequent and the yield is very low.
Beginner takeaway
The TEMA Oncology ETF provides exposure to cancer-fighting medical companies. While it has seen significant growth over the last three years, its long-term five-year performance has been negative. Investors should look at both the price return and the total return to get a full picture of performance.
Top Holdings
Structured portfolio holdings supplied by the ETF data provider. These figures are not generated by the AI article.
| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | REVOLUTION MEDICINES INC ORDINARY SHARES | RVMD | 6.05% |
| 2 | ELI LILLY AND CO | LLY | 4.93% |
| 3 | COGENT BIOSCIENCES INC | COGT | 4.92% |
| 4 | NOVARTIS AG REGISTERED SHARES | n/a | 4.01% |
| 5 | ROCHE HOLDING AG ADR | RHHBY | 3.76% |
| 6 | MERCK & CO INC | MRK | 3.39% |
| 7 | JOHNSON & JOHNSON | JNJ | 3.34% |
| 8 | LEGEND BIOTECH CORP ADR | LEGN | 3.27% |
| 9 | BRISTOL-MYERS SQUIBB CO | BMY | 3.25% |
| 10 | ABBVIE INC | ABBV | 3.23% |